 Scleroderma, Systemic
"Scleroderma, Systemic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Descriptor ID |
D012595
|
| MeSH Number(s) |
C17.300.799 C17.800.784
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Scleroderma, Systemic".
Below are MeSH descriptors whose meaning is more specific than "Scleroderma, Systemic".
This graph shows the total number of publications written about "Scleroderma, Systemic" by people in this website by year, and whether "Scleroderma, Systemic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 1 | 0 | 1 | | 1993 | 1 | 0 | 1 | | 1995 | 0 | 1 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 1 | 0 | 1 | | 2000 | 2 | 0 | 2 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 2 | 2 | | 2003 | 1 | 0 | 1 | | 2004 | 1 | 0 | 1 | | 2006 | 1 | 0 | 1 | | 2007 | 5 | 0 | 5 | | 2008 | 2 | 0 | 2 | | 2009 | 2 | 1 | 3 | | 2010 | 4 | 0 | 4 | | 2011 | 1 | 0 | 1 | | 2012 | 2 | 2 | 4 | | 2013 | 3 | 0 | 3 | | 2014 | 2 | 1 | 3 | | 2015 | 1 | 0 | 1 | | 2016 | 4 | 1 | 5 | | 2017 | 3 | 1 | 4 | | 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Scleroderma, Systemic" by people in Profiles.
-
Cottin V, Brown KK. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res. 2019 Jan 18; 20(1):13.
-
Fischer A, Zimovetz E, Ling C, Esser D, Schoof N. Humanistic and cost burden of systemic sclerosis: A review of the literature. Autoimmun Rev. 2017 Nov; 16(11):1147-1154.
-
Fischer A, Donnelly SC. Pulmonary fibrosis in connective tissue disease (CTD): urgent challenges and opportunities. QJM. 2017 08 01; 110(8):475-476.
-
Distler O, Brown KK, Distler JHW, Assassi S, Maher TM, Cottin V, Varga J, Coeck C, Gahlemann M, Sauter W, Schmidt H, Highland KB. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™). Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 106(4):75-81.
-
Morisset J, Vittinghoff E, Elicker BM, Hu X, Le S, Ryu JH, Jones KD, Haemel A, Golden JA, Boin F, Ley B, Wolters PJ, King TE, Collard HR, Lee JS. Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model. Chest. 2017 11; 152(5):999-1007.
-
Calderone A, Stevens W, Prior D, Nandurkar H, Gabbay E, Proudman SM, Williams T, Celermajer D, Sahhar J, Wong PK, Thakkar V, Dwyer N, Wrobel J, Chin W, Liew D, Staples M, Buchbinder R, Nikpour M. Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol. BMJ Open. 2016 12 08; 6(12):e011028.
-
Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 09; 4(9):708-719.
-
Khanna D, Albera C, Fischer A, Khalidi N, Raghu G, Chung L, Chen D, Schiopu E, Tagliaferri M, Seibold JR, Gorina E. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. J Rheumatol. 2016 09; 43(9):1672-9.
-
Aparicio IJ, Lee JS. Connective Tissue Disease-Associated Interstitial Lung Diseases: Unresolved Issues. Semin Respir Crit Care Med. 2016 06; 37(3):468-76.
-
Gao L, Emond MJ, Louie T, Cheadle C, Berger AE, Rafaels N, Vergara C, Kim Y, Taub MA, Ruczinski I, Mathai SC, Rich SS, Nickerson DA, Hummers LK, Bamshad MJ, Hassoun PM, Mathias RA, Barnes KC. Identification of Rare Variants in ATP8B4 as a Risk Factor for Systemic Sclerosis by Whole-Exome Sequencing. Arthritis Rheumatol. 2016 Jan; 68(1):191-200.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|